ISRCTN67246142 https://doi.org/10.1186/ISRCTN67246142

Phase 1 Trial: CA38132

Submission date 13/04/2024	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 15/04/2024	**Overall study status** Deferred	[ ] Statistical analysis plan [ ] Results
Last Edited 15/04/2024	**Condition category** Other	[ ] Individual participant data [ ] Record updated in last year

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Public, Scientific, Principal investigator

Contact name
Dr Nadine Abdullah

ORCID ID
https://orcid.org/0000-0001-7772-7724

Contact details
22-24 Lisburn Road
Belfast
United Kingdom
BT9 6AD
+442890 554040
nadine.abdullah@celerion.com

Additional identifiers

Integrated Research Application System (IRAS)
1006689

Protocol serial number
CA38132

Study information

Scientific Title
Phase 1 Trial: CA38132
The full scientific title will be published within 30 months after the end of the trial

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
1. approved 21/03/2023, London - London Bridge Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 2071048387; londonbridge.rec@hra.nhs.uk), ref: 22/LO/0842

2. approved 22/03/2023, MHRA (10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom; +44 2030806000; info@mhra.gov.uk), ref: CTA 52490/0004/001-0001

Study design
Phase 1 Safety Study

Primary study design
Interventional

Study type(s)
Safety

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s))
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
10/08/2023

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Upper age limit
55 years

Sex
All

Total final enrolment
51

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
13/04/2023

Date of final enrolment

03/07/2023

Locations

Countries of recruitment
United Kingdom

Northern Ireland

Study participating centre
Celerion GB Limited
22-24 Lisburn Road
Belfast
United Kingdom
BT9 6AD

Sponsor information

Organisation
Pliant (United States)

ROR
https://ror.org/02myr1w18

Funder(s)

Funder type
Industry

Funder Name
Pliant Therapeutics Inc.

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available